Multi-center Observational Study to Evaluate Epidemiology and Resistance Patterns of Common ICU-Infections (MOSER)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

381 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most literature on ICU infections and the resistant patterns comes from the western literature. This data may not truly reflect the incidence, epidemiology and resistance patterns in developing countries such as India. However, empiric antibiotic therapy is generally initiated using western guidelines. This can potentially lead to inadequate, inappropriate and ineffective empiric antibiotic therapy for ICU infections in the Indian setting. Hence in this multi-center observational study, we seek to:

1. To determine the incidence of ICU-related infections (VAP, CAUTI and CRBSI) in India
2. To explore the microbiology, resistance and treatment patterns of these infections

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome

NCT02683642

Mycoses

COMPLETED

NOSOcomial COVID-19 in ICU (NOSOCOVID)

NCT04659356

Coronavirus Infectious Disease (COVID-19) Nosocomial Infection Nosocomial COVID-19

UNKNOWN

Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients

NCT00410527

Bacterial Infections

COMPLETED PHASE4

Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection

NCT00438269

Nosocomial Infection Pneumonia Systemic Inflammatory Response Syndrome +2 more

COMPLETED PHASE2

COVID-19 and ICU-acquired MDR Bacteria

NCT04378842

Sars-CoV2 Critical Illness

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nosocomial Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICU infections

Infections acquired during the ICU stay

No intervention

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ICU stay \>48 hours
2. One of the following infections (VAP, CAUTI or CRBSI)

Exclusion Criteria

1. Index ICU stay \< 48 hours
2. Re-admissions to the ICU within the same hospitalization
3. Age \>18 years or \<70 years
4. Known HIV serology positivity
5. Burns
6. Solid organ or Bone-marrow transplant
7. No ICU-acquired infections (specifically VAP, CAUTI and CRBSI)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No